Corona Remedies

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE02ZQ01018
  • NSEID: CORONA
  • BSEID: 544644
INR
1,501.80
42.2 (2.89%)
BSENSE

Feb 03

BSE+NSE Vol: 75.02 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Cr
Consolidate Quarterly Results
Dec'25
Sep'25
Jun'25
Dec'24
Sep'24
Net Sales
342.42
361.13
346.54
297.69
313.87
Other Operating Income
0.00
0.00
0.00
0.00
0.00
Total Operating income
342.42
361.13
346.54
297.69
313.87
Raw Material Cost
24.82
25.90
25.07
24.71
28.56
Purchase of Finished goods
41.15
28.11
34.77
35.17
41.94
(Increase) / Decrease In Stocks
-5.70
14.64
5.94
-4.68
-7.90
Employee Cost
95.94
103.00
97.44
89.47
87.82
Power Cost
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
Other Expenses
103.05
111.01
113.54
83.60
96.63
Total Expenditure (Excl Depreciation)
259.26
282.66
276.76
228.27
247.05
Operating Profit (PBDIT) excl Other Income
83.16
78.47
69.78
69.42
66.82
Other Income
2.24
2.27
2.02
0.76
2.46
Operating Profit (PBDIT)
85.40
80.74
71.80
70.18
69.28
Interest
1.66
1.93
1.99
2.39
2.87
Exceptional Items
-19.10
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
64.64
78.81
69.81
67.79
66.41
Depreciation
9.45
9.20
8.92
9.69
9.05
Profit Before Tax
55.21
69.78
60.69
58.28
57.35
Tax
13.94
17.46
14.49
13.33
14.38
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
Profit After Tax
41.25
52.15
46.40
44.77
42.98
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
Net Profit
41.25
52.15
46.40
44.77
42.98
Share in Profit of Associates
0.02
0.17
-0.20
0.18
-0.01
Minority Interest
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
41.27
52.32
46.20
44.95
42.97
Equity Capital
61.16
61.16
61.16
61.16
61.16
Face Value
10.0
10.0
10.0
10.0
10.0
Reserves
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
6.75
8.55
7.55
7.35
7.03
Diluted Earnings per share
6.75
8.55
7.55
7.35
7.03
Operating Profit Margin (Excl OI)
24.29%
21.73%
20.14%
23.32%
21.29%
Gross Profit Margin
18.88%
21.82%
20.14%
22.77%
21.16%
PAT Margin
12.05%
14.49%
13.33%
15.1%
13.69%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Dec 2025 is -5.18% vs 4.21% in Sep 2025

stock-summary

Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -20.90% vs 12.39% in Sep 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is 5.98% vs 12.45% in Sep 2025

stock-summary

Interest

QoQ Growth in quarter ended Dec 2025 is -13.99% vs -3.02% in Sep 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

Compare Quarterly Results Of Corona Remedies With
Markets Mojo
Figures in Cr
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
342.42
535.90
-193.48
-36.10%
Other Operating Income
0.00
0.00
0.00
Total Operating income
342.42
535.90
-193.48
-36.10%
Raw Material Cost
24.82
75.70
-50.88
-67.21%
Purchase of Finished goods
41.15
84.10
-42.95
-51.07%
(Increase) / Decrease In Stocks
-5.70
80.70
-86.40
-107.06%
Employee Cost
95.94
53.80
42.14
78.33%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
103.05
69.70
33.35
47.85%
Total Expenditure (Excl Depreciation)
259.26
364.00
-104.74
-28.77%
Operating Profit (PBDIT) excl Other Income
83.16
171.90
-88.74
-51.62%
Other Income
2.24
3.30
-1.06
-32.12%
Operating Profit (PBDIT)
85.40
175.20
-89.80
-51.26%
Interest
1.66
0.30
1.36
453.33%
Exceptional Items
-19.10
0.00
-19.10
Gross Profit (PBDT)
64.64
174.90
-110.26
-63.04%
Depreciation
9.45
9.60
-0.15
-1.56%
Profit Before Tax
55.21
165.30
-110.09
-66.60%
Tax
13.94
45.80
-31.86
-69.56%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
41.25
119.50
-78.25
-65.48%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
41.25
119.50
-78.25
-65.48%
Share in Profit of Associates
0.02
0.00
0.02
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
41.27
119.50
-78.23
-65.46%
Equity Capital
61.16
23.00
38.16
165.91%
Face Value
10.00
10.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
6.75
51.96
-45.21
-87.01%
Diluted Earnings per share
6.75
51.89
-45.14
-86.99%
Operating Profit Margin (Excl OI)
24.29%
32.08%
0.00
-7.79%
Gross Profit Margin
18.88%
32.64%
0.00
-13.76%
PAT Margin
12.05%
22.30%
0.00
-10.25%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Quarterly - Net Sales
Net Sales 342.42 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is -5.18% vs 4.21% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 15.03%

Quarterly - Standalone Net Profit
Standalone Net Profit 41.25 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is -20.90% vs 12.39% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is -7.86%

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 83.16 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is 5.98% vs 12.45% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 19.79%

Quarterly - Interest
Interest 1.66 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is -13.99% vs -3.02% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is -30.54%

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 24.29%
in Dec 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024